Table 2 Comparison of patients with DCM treated with atorvastatin with and without AF.
Patients treated with ATORVASTATIN | |||
|---|---|---|---|
PARAMETER | AF Group n = 17 | No AF Group n = 27 | p |
Signs of heart failure | |||
dyspnoea (1)* | 9 (53%) | 8 (30%) | ns |
dyspnoea (2)* | 5 (29%) | 7 (26%) | ns |
oedema (1) | 4 (23.5)% | 2 (7.5%) | ns |
oedema (2) | 2 (11.7%) | 1 (4%) | ns |
pulmonary haemostasis (1) | 2 (11.7%) | 2 (7.5%) | ns |
pulmonary haemostasis (2) | 1 (5.8%) | 1 (4%) | ns |
Markers of inflammation | mean ± standard deviation | mean ± standard deviation | |
TNF-α (1) [pg/ml] | 21.54 ± 31.33 | 20.30 ± 21 | 0.25 |
TNF-α (2) [pg/ml] | 15.21 ± 20.15 | 9.56 ± 10.72 | 0.25 |
IL-6 (1) [pg/ml] | 17.91 ± 17.42 | 16.32 ± 12.76 | 0.72 |
IL-6 (2) [pg/ml] | 14.16 ± 13.40 | 6.74 ± 5.45 | 0.02 |
IL-10 (1) [pg/ml] | 9.98 ± 9.27 | 19.51 ± 32 | 0.28 |
IL-10 (2) [pg/ml] | 13.21 ± 9.53 | 31.40 ± 68.95 | 0.74 |
Heart Failure Assessment | |||
NT-proBNP (1) [pg/ml] | 2002.93 ± 1391.52 | 1518.87 ± 1732.83 | 0.14 |
NT-proBNP (2) [pg/ml] | 1530.62 ± 1054.27 | 1006.76 ± 1195.13 | 0.04 |
NYHA class (1) median | 2 | 3 | 0.35 |
NYHA class (2) median | 2 | 2 | 0.87 |
EF (1) [%] | 31.13 ± 7 | 29.82 ± 7.90 | 0.62 |
EF (2) [%] | 32 ± 8 | 32.00 ± 8.44 | 0.84 |
6-MWT (1) | 419.23 ± 72 | 376.09 ± 108.54 | 0.14 |
6-MWT (2) | 466.25 ± 104 | 441.84 ± 118 | 0.67 |